Lab Sciences
Top stories summarized by our editors
6/20/2017

The FDA accepted a new-drug application from Rigel Pharmaceuticals for Tavalisse, or fostamatinib disodium, an oral treatment for chronic or persistent immune thrombocytopenia.

6/20/2017

The anti-CD38 antibody daratumumab received FDA approval for use in combination with pomalidomide and dexamethasone as a third-line treatment for multiple myeloma. The drug was approved previously as a fourth-line treatment for certain patients.

6/20/2017

Labs are increasingly using liquid chromatography tandem-mass spectrometry for antifungal therapeutic drug monitoring because of increased sensitivity, specificity and rapid throughput compared with other methods. This piece discusses seven factors to consider when developing an LC-MS/MS method and notes that "future development should focus on simplifying the technology and making these complex instruments more affordable and robust, easier to use, and more open to automation."

6/20/2017

A blood test could help identify which advanced prostate cancer patients will respond to a type of targeted treatment called PARP inhibitors, as well as predicting how the drugs will affect their survival and how likely they are to develop resistance. Larger studies are still needed to determine whether doctors can rely on the test.

Full Story:
BBC, Medical News Today
6/16/2017

The National Institute for Health and Care Excellence has recommended use of Takeda's Adcetris, or brentuximab vedotin, as a treatment for adult patients with CD30-positive Hodgkin lymphoma who have relapsed or refractory disease following autologous stem cell transplant. Funding via the Cancer Drugs Fund was also backed by NICE for adult patients with CD30+ve R/R Hodgkin lymphoma who have had at least two previous therapies and for whom ASCT or multiagent chemotherapy are not treatment options.

Full Story:
PharmaTimes (U.K.)
6/16/2017

A histone deacetylases 1 and 2 inhibitor is being developed by researchers from the University of Utah's Huntsman Cancer Institute for the treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia. A study in the journal Leukemia found the drug was associated with 50% to 70% leukemia load reductions in tests of mice.

Full Story:
Nature World News
6/16/2017

Pennsylvania State University researchers have identified a Plasmodium falciparum protein that allows the parasite to enter red blood cells, according to a study in the journal Cell Host and Microbe. The next step will be to develop a drug candidate that blocks the protein PfAP2-I, lead researcher Manuel Llinas said.

Full Story:
Voice of America
6/15/2017

South Dakota reported its first case of West Nile virus infection in a human this year. West Nile-infected mosquitoes were reported in Ohio and California, and health officials urged people to take precautions to prevent mosquito bites.

6/15/2017

The University System of Maryland's Institute for Bioscience and Biotechnology Research has been awarded a $6 million, five-year grant by the NIH for the development of a hepatitis C virus vaccine.

More Summaries:
NIH
6/14/2017

Colombian researchers reviewed a case series involving 17 infants in Colombia whose mothers had Zika virus and found that serial ultrasound identified Zika-related microcephaly at a median gestational age of 28 weeks and a median of 18 weeks after the onset of maternal Zika virus symptoms. The findings in the journal Obstetrics & Gynecology also showed that three babies had evident congenital Zika syndrome symptoms such as ventriculomegaly and clubfoot prior to microcephaly diagnosis.

More Summaries:
microcephaly, ventriculomegaly